Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 106

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Blood blood.2024026388.

https://doi.org/10.1182/blood.2024026388

Published: 2024

Includes: Supplemental data

Journal Articles

Moving toward disease modification in polycythemia vera

Jan Philipp Bewersdorf, Joan How, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, John Mascarenhas, Raajit K. Rampal

Blood (2023) 142 (22): 1859–1870.

https://doi.org/10.1182/blood.2023021503

Published: 2023

Journal Articles

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

Joseph M. Scandura, Aaron T. Gerds, Ellen K. Ritchie, Xulong Wang, Steve Kye, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3211.

https://doi.org/10.1182/blood-2023-181720

Published: 2023

Journal Articles

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Keri Maher, Raajit K. Rampal, Prithviraj Bose, Nikolai A. Podoltsev, Claire N Harrison, Junshik Hong, Xulong Wang, Kamal Chamoun, John Mascarenhas

Blood (2023) 142 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2023-180695

Published: 2023

Journal Articles

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Helen Ajufo, Jan Philipp Bewersdorf, Claire N Harrison, Francesca Palandri, John Mascarenhas, Jeanne Palmer, Aaron T. Gerds, Jean-Jacques Kiladjian, Sarah Buckley, Andriy Derkach, Karisse Roman-Torres, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2023-177643

Published: 2023

Journal Articles

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Blood (2023) 142 (Supplement 1): 628.

https://doi.org/10.1182/blood-2023-179141

Published: 2023

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit K. Rampal, Natasha Novikov, Akshay Buch, Olivia Pelletier, William Savage, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4564.

https://doi.org/10.1182/blood-2023-174922

Published: 2023

Journal Articles

HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Antigen Presentation

Joseph Kim, Audrey-Ann Supreme, Bailey West, Mariah C. Antopia, Karen Reddy, Leslie Cope, Jung-Hyun Kim, Raajit K. Rampal, Richard Koche, Jerry L. Spivak, Alison R. Moliterno, Linda Resar

Blood (2023) 142 (Supplement 1): 992.

https://doi.org/10.1182/blood-2023-186452

Published: 2023

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit K. Rampal, Daniel J. DeAngelo, Virginia O. Volpe, Kristen Marie Pettit, Rami S. Komrokji, Eric Padron

Blood (2023) 142 (Supplement 1): 6441.

https://doi.org/10.1182/blood-2023-184652

Published: 2023

Journal Articles

Ubiquitin Ligase SCF-FBXO11 Controls a Network of RNA-Binding Proteins and Splicing in MDS

Madeline Niederkorn, Lavanya Bezavada, Anitria Cotton, Lance Palmer, Trent Hall, Michael Schieber, Peng Xu, Mitchell Weiss, Raajit K. Rampal, John D. Crispino

Blood (2023) 142 (Supplement 1): 712.

https://doi.org/10.1182/blood-2023-187094

Published: 2023

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease

Gaurav Goyal, Anne Reiner, Dana Bossert, Allison Sigler, Justin Buthorn, Mario Lacouture, Veronica Rotemberg, Jasmine H Francis, Ronald S. Go, Raajit K. Rampal, Eli L. Diamond

Blood (2023) 142 (Supplement 1): 4557.

https://doi.org/10.1182/blood-2023-184879

Published: 2023

Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 1519.

https://doi.org/10.1182/blood-2023-182012

Published: 2023

Journal Articles

MPN Transformation Is Characterized By Heterogeneous Shifts in Lineage Character

Deepika Dilip, Kamal Menghrajani, Jacob Glass, Raajit K. Rampal, Christopher Famulare, Maria Sirenko, Ross L Levine, Richard Koche

Blood (2023) 142 (Supplement 1): 749.

https://doi.org/10.1182/blood-2023-189767

Published: 2023

Journal Articles

Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms

Eli L. Diamond, Benjamin Durham, Ahmet Dogan, Mariko Yabe, Kseniya Petrova-Drus, Raajit K. Rampal, Raajit K. Rampal, Gary Ulaner, Mario Lacouture, Veronica Rotemberg, Anne Covey, Lynn Brody, Omar Abdel-Wahab

Blood (2023) 142 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2023-187508

Published: 2023

Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

Blood (2023) 142 (Supplement 1): 3192.

https://doi.org/10.1182/blood-2023-174790

Published: 2023

Journal Articles

A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Jan Philipp Bewersdorf, Andriy Derkach, Lucia Masarova, Naveen Pemmaraju, Eytan M. Stein, Michael Mauro, Raajit K. Rampal, Prithviraj Bose

Blood (2023) 142 (Supplement 1): 6440.

https://doi.org/10.1182/blood-2023-174322

Published: 2023

Journal Articles

Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool

Ryan P. Topping, Prithviraj Bose, John Mascarenhas, Raajit K. Rampal, Brady L. Stein, Timothy A. Quill, Ruben A. Mesa

Blood (2023) 142 (Supplement 1): 7291.

https://doi.org/10.1182/blood-2023-174268

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

NARROW

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Moving toward disease modification in polycythemia vera

A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naïve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Antigen Presentation

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Ubiquitin Ligase SCF-FBXO11 Controls a Network of RNA-Binding Proteins and Splicing in MDS

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Long-Term Outcomes with Single-Agent BRAF-Inhibitor Therapy in Erdheim-Chester Disease

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

MPN Transformation Is Characterized By Heterogeneous Shifts in Lineage Character

Phase 2 Trial of Single-Agent Cobimetinib for Adults with Histiocytic Neoplasms

Outcomes of Patients with Accelerated/Blast-Phase MPNs That Received Allogeneic Stem-Cell Transplant in the Current Era of Myeloid Therapies

A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Clinical Practice Gaps in Managing Patients with Myelofibrosis: Comparison of Healthcare Professional and Expert Treatment Choices Provided to an Online Decision Support Tool

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only